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Abstract 
In Australia, patients who want to access medicines that are not yet approved have 
only two options: to enrol in a clinical trial if they are eligible, or obtain their 
medicine through ‘compassionate supply’, which is provided at the discretion of the 
manufacturer. In this article, we explore ethical issues associated with the provision 
of oncology medicines that are still in development, either prior to regulatory 
approval or government reimbursement. 
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Introduction 
 
The possibility of developing cancer is a terrifying prospect for most people. It is 
unsurprising, therefore, that media reports relating to “breakthroughs” in the fight 
against the disease invariably capture the attention of the Australian public. 
 
Stories of promising early clinical trial data presented in the media—as well as at 
conferences, in medical journals, and via the Internet—may also prompt interest 
from patients, their relatives and their doctors to gain access to new agents without 
the need to wait years for their regulatory approval. 
 
Patients desiring access to medicines that are not yet approved generally have only 
two options: to enroll in a clinical trial if they are eligible (although this does not, of 
course, guarantee allocation to the new experimental treatment) or to ask the 
manufacturer to supply the medicine on “compassionate” grounds. The recent story 
of Nick Auden illustrates what happens when both of these options fail.  
 
Nick Auden was an Australian patient and young father, who died in 2013 from 
advanced metastatic melanoma. He and his family attempted, unsuccessfully, to gain 
2 
 
 
 
access to two ‘promising’ new therapies currently under development— nivolumab 
(Bristol-Myers-Squibb) and lambrolizumab (Merck). While not approved by any 
international regulatory bodies, these two drugs had shown promise in phase I 
clinical trials, and at the time of Auden’s approach to the two companies patients 
were being enrolled into phase II and III studies.  
 
Advanced metastatic melanoma has a very poor prognosis, with an overall 5 year 
survival being 10-20%.(1) Conventional therapies such as surgery, radiotherapy, 
cytokines and established chemotherapeutic agents (such as dacarbazine, 
temozolamide, paclitaxel, cisplatin) offer little more than short-term palliative 
benefits for many patients. For this reason, enormous excitement has surrounded 
the emergence of newer targeted therapies (vemurafenib and ipilimumab) as early 
studies have suggested a clinical benefit with relative increases in average patient 
survival of 63% and 36% respectively.(2) (3) 
 
However, because neither nivolumab or lambrolizumab were approved by the 
Therapeutic Goods Administration (TGA), and because he was not eligible to 
participate in phase II or III studies, Auden, his family and other high profile 
advocates pleaded for “compassionate access” from the companies developing 
these two medicines. The two companies, however, refused his requests, despite his 
case gaining international media coverage and a petition signed by many thousands 
of supporters. 
 
The public disquiet surrounding this case, and many others like it, illustrate a number 
of ethical, legal, commercial and socio-political challenges associated with 
compassionate access to cancer medicines, particularly those still in clinical 
development. In this article we describe features of compassionate access processes 
in Australia, highlight their limitations, and suggest the kinds of changes that might 
be required to ensure more appropriate and equitable access to prescription 
medicines.   
 
Compassionate access to cancer medicines in Australia 
 
The most common mechanism for patients to access currently unapproved or 
approved but unfunded treatments is through patient access programs (PAPs)—also 
referred to as “compassionate use”, “named patient” or “expanded access” 
programs. These programs, run by pharmaceutical companies, make drugs available 
(often, but not always, for free(4)) to patients within a structured company-
administrated framework. Inclusion criteria are usually similar to, but less rigorous 
than, those of a clinical trial, and tend to be closely aligned to the indication being 
sought by the company for their new product.  
Companies usually decide to institute PAPs following the emergence of phase III 
clinical trial data (i.e. data on efficacy and safety in patients with the relevant 
indication), and after an assessment of whether existing data is likely to support the 
eventual commercial launch of the new drug. In Australia, the ability to prescribe 
non-approved treatments is legislated for via the Australian Therapeutics Good 
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Administration Category A Special Access Scheme. This provides clinicians with the 
authority to prescribe non-approved treatments in the setting of a life-threatening 
condition. 
Outside of formal patient access programs, patients can approach companies with 
individual requests for supply of a desired medicine. They can also purchase the 
medicine themselves, either locally if it is available, or from another country where 
the treatment has regulatory approval. Companies may or may not help patients 
afford these medicines, which are often expensive, through various kinds of co-
payment or cost-sharing arrangements. Some hospitals also have high cost drug and 
therapeutics committees, which may agree to supply cancer medicines that are not 
approved by the TGA and/or not funded on the Pharmaceutical Benefits Scheme 
Companies’ obligations 
 
As is evident in Nick Auden’s case, companies are under no obligation to respond 
positively to requests for compassionate access. This is despite attempts made 
overseas to change this situation. In 2007, a group in the United States called the 
Abigail Alliance argued that both the United States Food and Drugs Administration 
(FDA) and pharmaceutical companies, had an obligation to provide early access to 
life-saving medicines.(5) 
 
The Abigail Alliance claimed, on libertarian grounds, that if a terminally ill patient 
had a fundamental right to refuse life-sustaining treatment, knowing that they 
would die as a consequence of that choice (a statute ruling from previous US cases), 
a corollary had to be that terminally ill patients should have the right to access any 
treatment that may extend or improve the quality of their lives, including those still 
in development. In rejecting this proposal, the FDA countered that such access 
would undermine the entire clinical research process and thus have a ‘devastating’ 
impact on the interest of future patients.(6) Following the failure of the Abigail 
Alliance’s case, at the current time, patients like Nick Auden have no option but to 
continue to lobby for compassionate access to medicines—leaving pharmaceutical 
companies to make their own decisions about whether or not they are able to help. 
 
At present, each pharmaceutical company independently determines when to allow 
compassionate access to its products, who should receive such access, and for how 
long. As Auden’s and other previous cases that led to the Abigail Alliance’s actions 
have illustrated, decisions relating to ad hoc requests can be highly controversial, 
leaving some patients feeling that they have been abandoned for unjustifiable 
reasons.  This, in turn, raises the question of how decisions about compassionate 
supply should be made and how compassionate access programs should be designed 
and overseen.  
 
Ethical considerations and tensions in the provision of compassionate access 
There are a number of tensions inherent in the provision of compassionate access to 
cancer medicines, resulting from a complex interplay among medical need, evidence, 
4 
 
 
 
ethics, medical law and commercial interest. 
The first of these is the tension between providing benefit to patients without 
causing harm to them, to those supporting them, to the health system, or to the 
research enterprise. Although robust clinical research and regulatory processes take 
time and delay access to medicines, they have evolved for good reason and history 
has demonstrated that significant harms may arise where medications are 
inadequately researched or regulated—such as occurred with rofecoxib(7) for 
arthritis and thalidomide for “morning sickness.”(8) Notwithstanding that 
‘risk/benefit’ considerations may be considerably different for patients with 
immanently life-threatening illnesses, as compared to patients with, say, morning 
sickness or arthritis, potential harms still need to be considered.(9) In this regard it is 
noteworthy that several cancer and HIV medicines that have been the source of 
initial excitement have subsequently failed to live up to their promise—even for 
people in desperate situations. These include, for example, cytokines for renal 
carcinoma(10), anti-angiogenic therapies for breast cancer(11) and some earlier anti-
retroviral drugs used in the treatment of AIDS.(12) In the context of life-threatening 
illness, we also need to bear in mind that effective palliation may be foregone if 
patients are led to believe that an expensive new treatment is their “only hope”. This 
lost opportunity is a real harm that needs to be factored into any risk—benefit 
calculation. 
Second, because resources are limited (even for companies, as will be discussed 
later) decisions have to be made about who should be privileged in terms of 
compassionate access. This inevitably creates a tension between allocating resources 
efficiently, so that the greatest amount of good is done for the greatest number of 
patients, and allocating resources in such a way that no particular individual or group 
is disadvantaged.(4) 
Third, as was evident in the Abigail Alliance debate, there is a tension between 
clinical care, which focuses on the needs of current patients, and research, which is 
primarily concerned about future and, ultimately, many more patients. If enough 
patients receive supply of a medication outside of the clinical trial setting, then 
opportunities are lost to gather crucial data on safety and efficacy. Trials might also 
be impacted if compassionate access makes it difficult for manufacturers to supply 
enough medicines needed for research. 
Finally, there are tensions between the needs of patients (both current and future) 
and the need for pharmaceutical companies to ensure early and maximal 
commercial returns. Pharmaceutical companies are businesses, and compassionate 
supply of their medicines may or may not be aligned with their longer-term 
commercial interests. On the one hand, as critics of industry have argued, companies 
may use compassionate access schemes as marketing tools designed to familiarize 
prescribers with their products, to create demand among patients and consumer for 
access and continued supply of these medicines, and to generate support from 
patients and clinicians for submissions to regulatory and funding bodies.(13) On the 
other hand, compassionate supply may work against the commercial interests of 
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companies, costing them money and diminishing community advocacy for third 
party (government or insurance company) funding as a means to access, thus 
reducing long-term revenues for manufacturers.  
So, with these tensions in mind, what might be a scientifically, ethically, politically 
and commercially sound approach to early access to potentially life-saving 
medicines? 
The future of compassionate access programs 
The first thing for those considering compassionate supply or designing 
compassionate access programs is to acknowledge there is no simple solution to any 
of the tensions described above, and it is therefore unlikely that a satisfactory  “one 
size fits all” process will ever be defined. Indeed, as described above, numerous 
models exist for patient access programs and there is significant heterogeneity 
between these.  
In all cases, therefore, engagement between companies and other stakeholders who 
may be impacted, such as clinicians, patients and regulators should occur to ensure 
that values are made explicit, that all interests are considered, and that trade-offs 
are acknowledged and managed. In technically complicated and value-laden 
processes such as these, it may be important to establish an appropriate forum that 
brings together representatives of industry, consumers, government, health 
providers, insurers, physicians, researchers and ethicists to develop a framework for 
patient access programs and, where resources are available, to review and advise on 
specific programs. While it is beyond the scope of this article to consider the details 
of how such a forum should be established and run, it could draw upon frameworks 
for policymaking such as “accountability for reasonableness”(14) as this emphasizes 
inclusive, transparent, accountable processes rather than on pre-refined rules of 
allocation.  
Second, properly informed consent should always be obtained—particularly when 
the treatment has not yet been approved by a regulatory agency. Patients 
requesting compassionate access are highly vulnerable and may feel a genuine sense 
of desperation, but they still need to understand the risks of bypassing research and 
regulatory processes, and the decision has to be theirs and not their family’s or their 
doctor’s.  
Once access has been granted and consent obtained, patients need to be carefully 
monitored for adverse events. In this regard it is noteworthy that, while, as 
discussed above, some PAPs require approval by health authorities prior to opening 
within hospitals under their jurisdiction, these programs rarely go through a human 
research ethics committee (HREC) review process. Indeed, data collection is often 
kept to a minimum in order to avoid the need for such review. The explicit 
justification for this is that the need for review may delay patient access to, and 
clinician experience of, a new product. Implicitly, reluctance to collect data and 
submit it for review may be in conflict with the commercial interests of a company 
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wishing to launch a new product as quickly as possible. Whatever the reason for 
bypassing review, the absence of sufficient oversight by HRECs may place patients at 
greater risk than those enrolled in clinical trials if a treatment is very early in its 
development and also limit the extent to which PAPs can be used as alternative 
sources of data about safety and efficacy. Because of this it is important that 
appropriate safeguards are in place to protect the interests of the most vulnerable of 
patients.  
In terms of forward planning, it is important for any company to consider the 
possibility that they might never achieve either regulatory approval or 
reimbursement, and to ask themselves what this would mean for the future of 
patients enrolled in a PAP. One option would be to simply apply a ‘rule’ that the PAP 
runs for a limited time, as is the case with Patient Familiarization Processes (PFPs). 
Under the rules of Medicines Australia Code of Conduct, PFPs may run for only 6 
months. However, while the application of such a rule to PAPs provides 
transparency, clarity and consistency, it may not adequately account the many 
complex factors that underpin decisions to provide compassionate access. 
A different approach, however, could take the form of single arm phase IV studies. 
These would have the benefit of generating useful additional evidence relating to 
safety, quality of life or other response-related endpoints. They may also help to 
generate evidence for outcomes that are difficult to demonstrate through 
randomized controlled trials due, for example, to confounding caused by crossover 
or post-study exposure to study treatments.(15). Indeed, compared to evidence 
generated within ‘artificial’ parameters of an RCT such activity may also be more 
reflective of the clinical effectiveness of a new treatment within a local and, because 
of less stringent inclusion criteria, a more diverse patient population. Such studies 
would, however, be reliant upon good biobank and patient registry infrastructure 
and would need to be managed very carefully so as not to compete with patient 
recruitment to clinical trials. 
One other issue that needs to be considered is that pharmaceutical companies are 
only one “player” in this complex field. While the focus of our discussion has been on 
medicines that have not yet received regulatory approval, compassionate access 
programs exist in part because governments and/or private insurers may choose not 
to fund even those medicines that have been shown to be safe and effective (but 
may not be cost effective)—such as trastuzumab (Herceptin) for metastatic breast 
cancer. This raises a whole suite of issues about the organization and priorities of the 
public and private health systems that are beyond the scope of this article. But it is 
important to bear in mind that ensuring access to life-saving medicines is a shared 
responsibility that falls to many different stakeholders, each of whom is driven by a 
complex set of moral and socio-political concerns.  
Conclusion 
Despite some media reports to the contrary, decisions about compassionate supply 
of cancer medicines that are still to be approved is not a simple matter of helping, or 
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not helping, an individual in need. Rather, they involve highly complex decisions that 
raise many ethical, regulatory, commercial, scientific and clinical tensions, all of 
which need to be considered and balanced.   
Importantly, the potential risk that PAPs may undermine or circumvent carefully 
structured processes for drug approval needs to be managed. This is because history 
provides us with a number of examples of drugs that initially appeared promising, 
but which were later found to be unsafe or of less clinical value than initially 
believed. In the context of cancer and other life-threatening illnesses where patients 
may be desperate for help and clinicians may feel enormous pressure to use 
whatever experimental treatments are available, it cannot be forgotten that 
appropriate palliative care may a more suitable option for some patients than access 
to treatments that may well prove to be ineffective and/or unsafe. For these 
reasons, the interests of both present and future patients need to be carefully 
considered, with decisions made in ways that are systematic, transparent, 
accountable, explicit about values, respectful of patient autonomy, and inclusive of 
all stakeholder perspectives.  
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